The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brodmerkel, C. M.
Right arrow Articles by Vaddi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brodmerkel, C. M.
Right arrow Articles by Vaddi, K.
The Journal of Immunology, 2005, 175: 5370-5378.
Copyright © 2005 by The American Association of Immunologists

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

Carrie M. Brodmerkel, Reid Huber, Maryanne Covington, Sharon Diamond, Leslie Hall, Robert Collins, Lynn Leffet, Karen Gallagher, Patricia Feldman, Paul Collier, Mark Stow, Xiaomei Gu, Frederic Baribaud, Niu Shin, Beth Thomas, Tim Burn, Greg Hollis, Swamy Yeleswaram, Kim Solomon, Steve Friedman, Anlai Wang, Chu Biao Xue, Robert C. Newton, Peggy Scherle and Kris Vaddi1

Incyte Corporation, Wilmington, DE 19880

This report describes the characterization of INCB3344, a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor. The lack of rodent cross-reactivity inherent in the small molecule CCR2 antagonists discovered to date has precluded pharmacological studies of antagonists of this receptor and its therapeutic relevance. In vitro, INCB3344 inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM) and displays dose-dependent inhibition of CCL2-mediated functional responses such as ERK phosphorylation and chemotaxis with similar potency. Against a panel of G protein-coupled receptors that includes other CC chemokine receptors, INCB3344 is at least 100-fold selective for CCR2. INCB3344 possesses good oral bioavailability and systemic exposure in rodents that allows in vivo pharmacological studies. INCB3344 treatment results in a dose-dependent inhibition of macrophage influx in a mouse model of delayed-type hypersensitivity. The histopathological analysis of tissues from the delayed-type hypersensitivity model demonstrates that inhibition of CCR2 leads to a substantial reduction in tissue inflammation, suggesting that macrophages play an orchestrating role in immune-based inflammatory reactions. These results led to the investigation of INCB3344 in inflammatory disease models. We demonstrate that therapeutic dosing of INCB3344 significantly reduces disease in mice subjected to experimental autoimmune encephalomyelitis, a model of multiple sclerosis, as well as a rat model of inflammatory arthritis. In summary, we present the first report on the pharmacological characterization of a selective, potent and rodent-active small molecule CCR2 antagonist. These data support targeting this receptor for the treatment of chronic inflammatory diseases.




This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
M Hegen, J C Keith Jr, M Collins, and C L Nickerson-Nutter
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis
Ann Rheum Dis, November 1, 2008; 67(11): 1505 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Buntinx, B. Hermans, J. Goossens, D. Moechars, R. A. H. J. Gilissen, J. Doyon, S. Boeckx, E. Coesemans, G. Van Lommen, and J. P. Van Wauwe
Pharmacological Profile of JNJ-27141491 [(S)-3-[3,4-Difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl Acid Methyl Ester], as a Noncompetitive and Orally Active Antagonist of the Human Chemokine Receptor CCR2
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 1 - 9.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. M. Handel, Z. Johnson, D. H. Rodrigues, A. C. dos Santos, R. Cirillo, V. Muzio, S. Riva, M. Mack, M. Deruaz, F. Borlat, et al.
An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo
J. Leukoc. Biol., October 1, 2008; 84(4): 1101 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Deruaz, A. Frauenschuh, A. L. Alessandri, J. M. Dias, F. M. Coelho, R. C. Russo, B. R. Ferreira, G. J. Graham, J. P. Shaw, T. N.C. Wells, et al.
Ticks produce highly selective chemokine binding proteins with antiinflammatory activity
J. Exp. Med., September 1, 2008; 205(9): 2019 - 2031.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R.-N. E. Dogan, A. Elhofy, and W. J. Karpus
Production of CCL2 by Central Nervous System Cells Regulates Development of Murine Experimental Autoimmune Encephalomyelitis through the Recruitment of TNF- and iNOS-Expressing Macrophages and Myeloid Dendritic Cells
J. Immunol., June 1, 2008; 180(11): 7376 - 7384.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
G. H. Tesch
MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy
Am J Physiol Renal Physiol, April 1, 2008; 294(4): F697 - F701.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Shahrara, A. E. I. Proudfoot, C. C. Park, M. V. Volin, G. K. Haines, J. M. Woods, C. H. Aikens, T. M. Handel, and R. M. Pope
Inhibition of Monocyte Chemoattractant Protein-1 Ameliorates Rat Adjuvant-Induced Arthritis
J. Immunol., March 1, 2008; 180(5): 3447 - 3456.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Mohan and T. B. Issekutz
Blockade of Chemokine Receptor CXCR3 Inhibits T Cell Recruitment to Inflamed Joints and Decreases the Severity of Adjuvant Arthritis
J. Immunol., December 15, 2007; 179(12): 8463 - 8469.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-S. Nam, M.-J. Kang, A. M. Suchar, T. Shimamura, E. A. Kohn, A. M. Michalowska, V. C. Jordan, S. Hirohashi, and L. M. Wakefield
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
Cancer Res., July 15, 2006; 66(14): 7176 - 7184.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.